Press Releases

Release year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Release Tag:

August 25, 2017
Genetic Technologies Announces Comprehensive Review of Strategic Alternatives

August 01, 2017
Genetic Technologies Launches Breast Cancer Awareness Month Promotion for BREVAGenplus(R)

July 27, 2017
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2017

July 21, 2017
Genetic Technologies Receives Nasdaq Deficiency Notice

March 31, 2017
Genetic Technologies Revamps Patient Pricing and Billing Program for BREVAGenplus(R)

March 29, 2017
Genetic Technologies and IndyCar's Pippa Mann Partner for Second Consecutive Year to Promote BREVAGenplus(R)

December 01, 2016
Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

November 29, 2016
Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License Agreement to Develop Colorectal Cancer Risk Assessment Test

October 19, 2016
Nohla Therapeutics Signs Exclusive Supply Agreement With LifeSouth Community Blood Centers

October 03, 2016
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for the Cure(R) Events

June 22, 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership

June 21, 2016
Genetic Technologies Announces Appointment of Senior Medical Director

May 04, 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closing Bell on May 6th, 2016

March 30, 2016
Opthea Completes Patient Enrolment for OPT-302 Phase 1 Dose Escalation Trial in Patients With Wet AMD

February 22, 2016
Genetic Technologies and IndyCar's Pippa Mann Announce Partnership to Promote BREVAGenplus(R)

December 21, 2015
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAGenplus(R)

October 30, 2015
ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences

October 16, 2015
Open Monoclonal Technology and ARMO BioSciences Announce Anti-PD1 Antibody and OmniAb(TM) Platform License Agreement

August 06, 2015
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R)

July 14, 2015
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication Initiatives

June 16, 2015
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering

June 16, 2015
Genetic Technologies Announces Appointment of Chief Financial Officer

May 28, 2015
SuperSonic Imagine Announces Regulatory Clearance of the Next-Generation Aixplorer(R) Ultrasound System in Japan

April 28, 2015
SuperSonic Imagine Announces Clinical Data From Its Retrospective Multicenter Trial Evaluating ShearWave(TM) Elastography for the Non-Invasive Staging of Patients With Chronic Liver Disease

April 23, 2015
SuperSonic Imagine's ShearWave(TM) Elastography Technology Will be Presented at the International Liver Congress (EASL) 2015 Vienna, Austria

April 20, 2015
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R)

April 15, 2015
SuperSonic Imagine's Aixplorer(R) Ultrasound System Highlighted at AIUM/WFUMB 2015

April 01, 2015
SuperSonic Imagine Appoints Tom Egelund as President and Chief Executive Officer

February 27, 2015
SuperSonic Imagine to Present at the Cowen and Company 35th Annual Health Care Conference on March 4, 2015

February 26, 2015
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer

January 29, 2015
Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R)

January 21, 2015
Genetic Technologies Secures A$24 Million Standby Equity Placement Facility

December 17, 2014
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment

December 02, 2014
3-V Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference

November 12, 2014
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial

November 10, 2014
Alchemia Announces Departure of Chief Executive Officer

October 26, 2014
Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer

October 09, 2014
Alchemia Announces Database Lock of Its HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer

October 06, 2014
Genetic Technologies Announces Quarterly BREVAGen(TM) Results

October 01, 2014
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test

September 24, 2014
Genetic Technologies Announces Appointment of Independent Non-Executive Directors

September 22, 2014
Genetic Technologies Announces Divestment of Australian Based Heritage Business

September 15, 2014
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing

August 26, 2014
Genetic Technologies Announces Further Patent Success in USA

August 25, 2014
Alchemia Appoints Jenni Pilcher as Chief Financial Officer

July 30, 2014
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec

July 07, 2014
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014

June 30, 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer

June 20, 2014
Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)

June 05, 2014
Alchemia Updates Timeline for Completion of Pivotal Phase III Trial of HA-Irinotecan in Metastatic Colorectal Cancer

May 28, 2014
Genetic Technologies Announces Appointment of Chief Financial Officer

May 16, 2014
Genetic Technologies Announces Completion of Share Transaction With Dr. Mervyn Jacobson

April 30, 2014
Genetic Technologies Files Activities Report for the Quarter Ended March 31, 2014

April 17, 2014
Results From Extraordinary General Meeting

April 07, 2014
Alchemia Announces Presentation of Data on Its Discovery of a Potential New Cancer Stem Cell Therapeutic Target During the 2014 AACR Annual Meeting

March 24, 2014
Genetic Technologies Executes Agreement With Promega Corporation

March 07, 2014
Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness of BREVAGen(TM) to Direct Tamoxifen Chemoprevention

March 03, 2014
Alchemia to Present at the 26th Annual ROTH Conference on March 12, 2014

February 27, 2014
Alchemia to Present at the Cowen and Company 34th Annual Health Care Conference on March 3, 2014

February 24, 2014
Genetic Technologies Provides Further Update on Corporate Structure

February 24, 2014
Alchemia Appoints Thomas Liquard as Chief Executive Officer

February 19, 2014
Alchemia Announces Quarterly Fondaparinux Profit Share

February 18, 2014
Alchemia Announces Half-Year Results for Period Ended 31 December 2013

February 18, 2014
Nexvet Biopharma to Present at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014

February 12, 2014
Genetic Technologies Announces Update on Intellectual Property

February 11, 2014
Alchemia Announces Appointment of Santo J. Costa as Chairman

January 30, 2014
Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013

January 08, 2014
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for December Quarter

December 23, 2013
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds

December 18, 2013
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder

December 06, 2013
Genetic Technologies Announces Publication Highlighting Cost-Effectiveness of BREVAGen(TM) in Cancer Prevention Research

October 31, 2013
Genetic Technologies Announces Financial Results for First Fiscal Quarter Ended September 30, 2013

October 15, 2013
Genetic Technologies Announces Temporary Corporate Restructure

October 01, 2013
Genetic Technologies Announces Record Quarter for BREVAGen(TM)

September 26, 2013
ImmunAid Limited Commences Second Round Fundraising Program

September 23, 2013
Achaogen Announces Agreement With FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

September 09, 2013
Aquilo Capital Management Submits Open Letter to the Board of Directors and Fellow Shareholders of Astex Pharmaceuticals

August 30, 2013
Genetic Technologies Receives Certification for New York State

August 20, 2013
Alchemia Reports Record Fondaparinux Quarterly Profit Share

August 05, 2013
Vital Therapies, Inc. Receives Orphan Designation in Europe

August 01, 2013
Genetic Technologies Announces Financing and Intended Use of Proceeds

July 10, 2013
Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid

July 01, 2013
Genetic Technologies Announces Record Number of BREVAGen(TM) Tests

June 24, 2013
Genetic Technologies Settles Its Dispute With Ingelheim, Germany-Based Bioscientia Institute for Medical Diagnostics

June 24, 2013
Genetic Technologies Announces Independent Clinical Validation Study in Support of the Utilization of BREVAGen(TM)

June 19, 2013
Genetic Technologies Executes Agreement With Further Nationwide Provider Network for BREVAGen(TM)

June 17, 2013
Genetic Technologies Provides U.S. Gene Patenting Update

May 22, 2013
Alchemia Limited Provides Company Update

May 20, 2013
Genetic Technologies Executes Agreement With MultiPlan, Inc., a Nationwide Provider Network

May 16, 2013
Vital Therapies, Inc. Adds Two New Board Members

May 09, 2013
Sunshine Heart, Inc. Announces First Patient Implanted in C-Pulse System European Post-Market Study

May 03, 2013
Genetic Technologies Executes Agreement With Nationwide Provider Network

April 30, 2013
Genetic Technologies Announces Financial Results for Quarter Ended March 31, 2013

April 23, 2013
Alchemia Announces Multi-Target Drug Discovery Collaboration With AstraZeneca on VAST Discovery Platform

April 16, 2013
Sunshine Heart, Inc. Closes Public Offering of Common Shares

April 11, 2013
Sunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares

April 10, 2013
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares

April 04, 2013
Vital Therapies, Inc. Enrolls First Patient in VTI-208, a Controlled, Randomized Phase 3 Trial Evaluating the ELAD(R) System in Alcohol-Induced Liver Decompensation

April 04, 2013
IDT Ltd Appoints Dr. Paul MacLeman CEO

March 25, 2013
Vital Therapies, Inc. Announces Increase in Financing

March 22, 2013
Alchemia Announces Addition of Two Board Members

March 15, 2013
Genetic Technologies Provides U.S. Patent Re-Examination Update

March 13, 2013
Sunshine Heart Appoints Jon Salveson to Board of Directors

March 11, 2013
Sunshine Heart Reports Fourth Quarter and Full Year 2012 Results

March 06, 2013
Alchemia Granted Key US Patent

March 06, 2013
SymBio Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

February 28, 2013
Alchemia Completes Enrolment in Pivotal Phase III HA-Irinotecan Trial of Metastatic Colorectal Cancer

February 26, 2013
Sunshine Heart to Attend Upcoming Investor Conferences

February 22, 2013
Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2012

February 18, 2013
Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share

February 18, 2013
Alchemia Appoints Charles Walker as Chief Executive Officer

February 12, 2013
Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update

January 30, 2013
Sunshine Heart Appoints Warren Watson to Board of Directors

January 29, 2013
Sunshine Heart to Delist From the Australian Securities Exchange

January 15, 2013
Sunshine Heart Enters Into a $25 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

January 07, 2013
Sunshine Heart Provides Clinical Update

December 10, 2012
Genetic Technologies Appoints Chief Executive Officer and Non-Executive Director

November 29, 2012
Genetic Technologies Provides Update on Board and Management Changes

November 20, 2012
Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial

November 14, 2012
Biota Pharmaceuticals Announces Appointment of New Executive Officers

November 08, 2012
Sunshine Heart Announces 3Q12 Financial Results

November 08, 2012
Sunshine Heart to Present at Upcoming Investor Conferences

November 07, 2012
Biota Receives $4.2m R&D Tax Credit

October 23, 2012
Biota Announces Shareholder Approval of Merger With Nabi Pharmaceuticals

October 23, 2012
Sunshine Heart Receives 2012 Frost & Sullivan North American Heart Failure Treatment New Product Innovation Award for C-Pulse(R)

October 23, 2012
Biota Announces Approval of Definitive Merger Agreement by Nabi Shareholders

October 18, 2012
Sunshine Heart's Feasibility Study Data to Be Presented at 2012 Transcatheter Cardiovascular Therapeutics Conference

October 15, 2012
Genetic Technologies Files Patent Infringement Suits Against Multiple Alleged Infringers in USA

October 11, 2012
Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program

October 01, 2012
Audeo Oncology Announces New Board Appointments

October 01, 2012
Sunshine Heart Announces Conditional Approval of IDE From the FDA for C-Pulse(R) Heart Assist System

September 27, 2012
Vital Therapies, Inc. Announces First Closing of $76 Million Staged Financing to Fund Phase 3 Pivotal Clinical Trials of ELAD(R) in USA and EU

September 25, 2012
Genetic Technologies Announces BREVAGen(TM) Attains Clearance for Sale Into Florida

September 18, 2012
Biota and Nabi Announce Revised Merger Terms

September 13, 2012
Sunshine Heart Appoints John Erb to Chairman of the Board

September 13, 2012
Genetic Technologies Announces Key Managerial Appointment

August 30, 2012
Sunshine Heart Submits Investigational Device Exemption to FDA for C-Pulse(R) System Pivotal Trial

August 30, 2012
Genetic Technologies Files Patent Infringement Suit Against Reproductive Genetics Institute Inc. in USA

August 22, 2012
Biota Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study

August 15, 2012
Sunshine Heart Announces Closing of Public Offering of Common Stock

August 10, 2012
Sunshine Heart Announces $20.125M Public Raise

August 10, 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs

August 09, 2012
Biota Shareholders Meeting on Proposed Merger With Nabi

August 08, 2012
Genetic Technologies Receives CE Mark Approval for BREVAGen(TM)

August 06, 2012
Sunshine Heart Announces Conditional Approval From FDA for Its Next Generation C-Pulse(R) System Driver

July 30, 2012
Sunshine Heart Announces 2Q12 Financial Results

July 26, 2012
Genetic Technologies Announces BREVAGen(TM) Cleared for Sale in California

July 25, 2012
Sunshine Heart Announces CE Mark for C-Pulse(R) Heart Assist System

July 24, 2012
Genetic Technologies Appoints Mr. Greg Brown as Director

July 23, 2012
Sunshine Heart Announces First Patient Reaches Two-Year Follow-Up Mark for C-Pulse(R) Heart Assist System

July 09, 2012
Audeo Oncology, Inc. Files Registration Statement for Proposed Initial Public Offering

June 07, 2012
Sunshine Heart Receives Health Canada Approval to Modify Its Ongoing Investigational Study to Use the Next Generation C-Pulse(R) System Driver

June 04, 2012
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

May 31, 2012
Single Center Data From C-Pulse(R) Feasibility Trial in Patients With Moderate to Severe Heart Failure to Be Presented at the 2012 ISMICS Annual Meeting

May 22, 2012
Genetic Technologies Provides BREVAGen(TM) Sales and Reimbursement Update

May 17, 2012
Neuren Holds Pre-IND Meeting on Proposed Rett Syndrome Clinical Trials With FDA

May 11, 2012
Biota Announces Inavir(R) Royalty Results for Q312 and Phase III Prevention Study Update

May 10, 2012
Sunshine Heart Announces 1Q12 Financial Results

May 09, 2012
Genetic Technologies Executes Settlement and License Agreement With GeneSeek Inc.

April 23, 2012
Biota and Nabi Announce Proposed Merger

April 13, 2012
Break-Through Invention for Treating Cancer -- Australian Biotech Company Completes Round 1 Funding

April 13, 2012
Genetic Technologies' Subsidiary Update

March 28, 2012
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human Rhinovirus Infection (HRV)

March 14, 2012
Sunshine Heart Announces FDA Completes Review of C-Pulse(R) Feasibility Data

March 12, 2012
Sunshine Heart Provides FAQ Regarding Transmutation of CDIs to Common Stock

March 08, 2012
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results

March 06, 2012
Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical Study at the 2012 AACR Annual Meeting

February 29, 2012
Genetic Technologies Provides Update on U.S. and Australian Gene Patenting Litigation, Case Law and Legislation

February 28, 2012
Alchemia to Present at the Cowen Health Care Conference

February 27, 2012
Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2011

February 24, 2012
Threshold Pharmaceuticals to Present at the Cowen Health Care Conference

February 21, 2012
Genetic Technologies Successfully Concludes Second Patent Infringement Suit in USA

February 21, 2012
Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

February 17, 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer

February 16, 2012
Sunshine Heart Announces NASDAQ Listing

February 16, 2012
Genetic Technologies Receives CLIA Certificate of Compliance From Centers for Medicare and MedicAid Services, USA

February 15, 2012
Biota Announces Financial Results for First Half of Fiscal 2012

February 06, 2012
Genetic Technologies Executes Settlement and License Agreement With Eurofins STA Laboratories, Inc.

February 03, 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302

January 31, 2012
Genetic Technologies Files Quarterly Activities Report and ASX Appendix 4C for Quarter Ended December 31, 2011

January 04, 2012
Phylogica Licenses Technology to Janssen Biotech, Inc.

January 04, 2012
Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan in Metastatic Colorectal Cancer

December 16, 2011
Genetic Technologies Appoints Dr. Mel Bridges as Chairman

December 15, 2011
Phylogica and Pfizer Complete First Stage of Peptide Vaccine Collaboration

December 14, 2011
Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias

December 13, 2011
Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference

December 01, 2011
Sunshine Heart to Present at The Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference

November 29, 2011
Threshold Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

November 23, 2011
Sunshine Heart to Present at The Piper Jaffray Healthcare Conference

November 03, 2011
Threshold Pharmaceuticals Reports Third Quarter 2011 Financial and Operational Results

November 02, 2011
Threshold Pharmaceuticals Appoints Nipun Davar as Vice President of Pharmaceutical Development and Manufacturing

November 01, 2011
Threshold Pharmaceuticals to Present at the Lazard Healthcare Conference

October 28, 2011
Threshold Pharmaceuticals Reports Further Promising Data With TH-302 in Soft Tissue Sarcoma

October 18, 2011
ALLOZYNE Announces Positive Results From Phase 1B Trial of AZ01

October 06, 2011
Threshold Pharmaceuticals to Present at the BioCentury NewsMakers Conference

September 30, 2011
Threshold Pharmaceuticals Initiates Phase 3 TH-302 Combination Trial in Advanced Soft Tissue Sarcoma

September 22, 2011
Threshold Pharmaceuticals to Present at the JMP Securities Healthcare Conference

September 19, 2011
Sunshine Heart Raises A$7.4 Million in Two-Tranche Private Placement

September 16, 2011
Sunshine Heart to Present at Lazard Capital Markets Circulatory Assist Device Day

September 06, 2011
Threshold Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Healthcare Conference

September 02, 2011
Threshold Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference

August 17, 2011
Biota Announces Preliminary Full Year Report

October 21, 2010
Biota Announces Relenza September Quarter Royalty